Importantly, modulation of the AMPK pathway may allow targeting of mTOR in a distinct, non-overlapping way, from mTOR inhibitors and other suppressors of the PI3'K/AKT/mTOR cascade and AMPK activators could be potentially combined with PI 3'K/mTOR inhibitors in the treatment of refractory myeloid leukemias. Here, AKT1 is linked to myeloid leukemia.